ライフサイエンスコーパス: nonmalignant

1 n in malignant T24 bladder cells, but not in nonmalignant 293 or NIH 3T3 cells.

2 ably expressing luciferase are cultured with nonmalignant accessory cells (for example, stromal cells

3 ulated in malignant cell lines compared with nonmalignant acini.

4 DIs (aIRR, 1.52; 95% CI, 1.25-1.86) than for nonmalignant ADIs (aIRR, 1.12; 95% CI, 1.01-1.25), compa

5 sed screening and bisulfite sequencing of 20 nonmalignant and 29 PC tissue specimens were used to ide

6 NA metabolism elicits different responses in nonmalignant and cancer cells and suggests that the abno

7 menin may be important in the regulation of nonmalignant and CCA proliferation and may be an additio

8 egulated, and the molecular underpinnings of nonmalignant and malignant hematologic disorders.

9 successful treatment for many patients with nonmalignant and malignant liver diseases.

10 for somatic mutations in the pathogenesis of nonmalignant and/or autoimmune hematologic conditions in

11 ere found when transudative pleural fluid or nonmalignant ascites was used as surrogates for extravas

12 enhanced MR imaging that subsequently proved nonmalignant at biopsy were retrospectively reviewed.

13 n humans is a major trigger of malignant and nonmalignant B cell proliferations.

14 ese results indicate that although silent in nonmalignant B cells, a defect in the INK4-Cdk4 checkpoi

15 t distinguished patients with malignant from nonmalignant biopsies.

16 nantly phosphoproteins) in matched tumor and nonmalignant biopsy specimens from 23 patients with head

17 retreatment esophageal adenocarcinoma and 49 nonmalignant biopsy tissues from patients undergoing end

18 10-fold higher ClC-3 protein expression than nonmalignant brain.

19 l cells from either reduction mammoplasty or nonmalignant breast cell lines, we observed a unique cel

20 upregulated in malignant cells compared with nonmalignant breast cells.

21 d a three-dimensional culture model in which nonmalignant breast epithelial cells form spheroids remi

22 This receptor complex acutely sensitizes nonmalignant breast epithelial cells to activation by ty

23 1-integrin and NF-kappaB p65 were induced in nonmalignant breast epithelial cells, but not in maligna

24 One hundred seventy-five nonmalignant breast lesions in 165 women were evaluated.

25 ast tumors are stiffer and more hypoxic than nonmalignant breast tissue.

26 r compared with ductal carcinoma in situ and nonmalignant breast, and cellular BCL6 protein levels co

27 ke alveolar malignant cell line (A549) and a nonmalignant bronchial epithelial cell line (BEAS-2B).

28 was higher in lung cancer cell lines than in nonmalignant bronchial epithelial cells.

29 t has showed significant differences between nonmalignant cancer cells and the cancerous ones for bot

30 ant lesions was significantly higher than in nonmalignant cases (13.2 +/- 6.2 vs. 2.3 +/- 1.2, P = 0.

31 or the differentiation between malignant and nonmalignant cases.

32 city for tumor vasculature and the different nonmalignant causes that can impact CEC.

33 with malignant CBD stenoses than controls or nonmalignant CBD stenoses (2.41 x 10(15) vs 1.60 x 10(14

34 this threshold discriminated malignant from nonmalignant CBD stenoses with 100% accuracy.

35 hed patients with malignant vs patients with nonmalignant CBD stenoses with 63.3% diagnostic accuracy

36 Vs in bile could discriminate malignant from nonmalignant CBD stenoses.

37 riminates between patients with malignant vs nonmalignant CBD stenosis with 100% accuracy.

38 NOX2 inhibition had no detectable effect on nonmalignant CD34(+) cell survival.

39 Although mitochondrial transfer from BMSC to nonmalignant CD34(+) cells occurs in response to oxidati

40 ls have increased mitochondria compared with nonmalignant CD34(+) hematopoietic progenitor cells.

41 tions of malignant Sezary cells (SCs) versus nonmalignant CD4(+) T cells from 3 patients for whole tr

42 arger in cancerous bladder cells compared to nonmalignant cell cancer of the ureter (HCV29 cells).

43 mors when compared with normal tissues and a nonmalignant cell line and is correlated inversely with

44 y in young adult mouse colonocytes (YAMC), a nonmalignant cell line, in a dose-responsive manner.

45 ines as well as cancer tissues compared with nonmalignant cell lines or normal tissues.

46 grin heterodimer expression in malignant and nonmalignant cell lines.

47 CLCs) but have AMPK-activating properties in nonmalignant cell types, we set out to investigate this

48 toxic (up to 100 muM) toward representative nonmalignant cells (fibroblasts).

49 expressed between resting and proliferating, nonmalignant cells (ie, a "proliferative signature") and

50 abnormalities and the genetic fingerprint of nonmalignant cells also contribute to the miRNA profile

51 However, such inhibitors may also affect nonmalignant cells and cause pronounced off-target effec

52 As a model for changes induced in nonmalignant cells by cancer, we examined T-cell functio

53 hibition of the myosin light-chain kinase in nonmalignant cells could recapitulate some of the mitoti

54 polarity: forced proliferation of polarized, nonmalignant cells did not induce VEGF expression and EC

55 rsion of malignant cells into phenotypically nonmalignant cells in 3D gels, we identified FAM83A as a

56 that these mimetics enhance the survival of nonmalignant cells in a zebrafish model of metastasis.

57 alpha2,6-SA and lower levels of LacNAc than nonmalignant cells in culture and in vivo and that nucle

58 effects of radiation exposure, predominantly nonmalignant cells in the tumor microenvironment manifes

59 a functional interplay between malignant and nonmalignant cells in the tumor microenvironment.

60 we show that increasing oxidative stress in nonmalignant cells induced their sensitization to the ef

61 n engineered, functionally inducible MMP9 in nonmalignant cells led to loss of tissue polarity, and r

62 We propose that antigen expression in nonmalignant cells may contribute to the efficacy of T-c

63 ggested the hypothesis that APN expressed by nonmalignant cells might promote tumor growth.

64 A variety of nonmalignant cells present in the tumor microenvironment

65 selectively targets mitochondria, cancer and nonmalignant cells respond differently to disruption of

66 Overexpression of PIP5K1alpha in PNT1A nonmalignant cells results in an increased AKT activity

67 T exhibits extremely low toxicity on several nonmalignant cells such as fibroblasts, normal bone marr

68 rs selective mRNA translation, reprogramming nonmalignant cells to an invasive phenotype by reducing

69 onducted a targeted chemical screen in human nonmalignant cells to validate known and search for nove

70 a differential behavior toward malignant and nonmalignant cells was observed for SeChry and SePQue, e

71 Perturbation of such boundaries in nonmalignant cells was sufficient to activate proto-onco

72 S analysis comparing conditioned medium from nonmalignant cells with or without active MMP9 revealed

73 d mitochondrial accumulation of FerT endowed nonmalignant cells with tumor-forming ability.

74 sion by CLL cells reflects interactions with nonmalignant cells within pseudofollicles in secondary l

75 -quadruplexes, their uptake in malignant and nonmalignant cells, and their capacity to modulate gene

76 In nonmalignant cells, AS was expressed at higher levels th

77 pression levels differed in malignant versus nonmalignant cells.

78 induced the anchorage-independent growth of nonmalignant cells.

79 ttle is known about how dasatinib influences nonmalignant cells.

80 or selective p53-dependent cytoprotection of nonmalignant cells.

81 ake, whereas no stimulation was observed for nonmalignant cells.

82 required to detect the fusion transcript in nonmalignant cells.

83 e production of proinflammatory cytokines by nonmalignant cells.

84 n largely limited to nonneural malignant and nonmalignant cells.

85 induce apoptosis in tumors without affecting nonmalignant cells.

86 compartmentalized pressure characteristic of nonmalignant cells.

87 In contrast, these effects did not occur in nonmalignant cells.

88 heterogeneous malignant cells and associated nonmalignant cells.

89 pathogenic microorganisms in cancer, but not nonmalignant cells.

90 nabled T cells to distinguish malignant from nonmalignant cells.

91 cer, n = 20 or cholangiocarcinoma, n = 5) or nonmalignant (chronic pancreatitis [CP], n = 15) origin.

92 roxysmal nocturnal hemoglobinuria (PNH) is a nonmalignant clonal disease of hematopoietic stem cells

93 on, depletion of Cdh1 by RNA interference in nonmalignant colon cells resulted in increased cellular

94 increased H2S production, compared with the nonmalignant colonic mucosa cells, NCM356.

95 oproliferative disorder (RALD) is a chronic, nonmalignant condition that presents with persistent mon

96 e importance and function of this pathway in nonmalignant conditions as well as malignancies (includi

97 ansplantation as a therapy for malignant and nonmalignant conditions is complicated by pulmonary infe

98 or chemotherapy in HSPC transplantation for nonmalignant conditions.

99 asingly used to treat multiple malignant and nonmalignant conditions.

100 patients admitted to the same hospitals for nonmalignant conditions.

101 gress in the treatment of many malignant and nonmalignant conditions.

102 iral infections after HSCT for malignant and nonmalignant conditions.

103 organ transplant, and immune suppression for nonmalignant conditions.

104 tigated in 93 tissue samples (39 CCAs and 54 nonmalignant controls) using quantitative methylation-sp

105 nvasive bladder cancer tissues compared with nonmalignant controls.

106 ysis, and the MCF-10A and MCF-7 were used as nonmalignant controls.

107 remained noninvasive; however, unlike their nonmalignant counterparts, they exhibited a high propens

108 uman endometrial tumors and cells with their nonmalignant counterparts, we found that upregulation of

109 mpared with their polarized, growth-arrested nonmalignant counterparts.

110 tic cancer or cholangiocarcinoma, n = 15) or nonmalignant (CP, n = 15) CBD stenosis.

111 cohort study of all patients (N = 671) with nonmalignant cytology who had thyroidectomy between Octo

112 erstandings about the trajectory of advanced nonmalignant disease among patients, families, and perha

113 he main risk factor for developing an AD was nonmalignant disease as an indication for CBT (P = .0001

114 iated with mortality from other malignant or nonmalignant disease, the authors examined the associati

115 ar complications compared with children with nonmalignant disease.

116 iatric AlloHCT recipients with malignant and nonmalignant disease.

117 ching in unrelated donor transplantation for nonmalignant diseases (NMD) has yet to be defined.

118 nts developing ADs were younger and had more nonmalignant diseases (P < .001).

119 ons in a variety of cancers and perhaps many nonmalignant diseases as well.

120 thesis also opened doors to treating various nonmalignant diseases characterized by abnormal vasculat

121 ed with many potentially fatal malignant and nonmalignant diseases is well recognized.

122 poietic stem cell transplantation (HSCT) for nonmalignant diseases result in increased risk for adver

123 Nonmalignant diseases such as bone marrow suppression an

124 The outcome in patients with nonmalignant diseases was acceptable, but transplant-rel

125 Nonmalignant diseases were associated with better 5-year

126 lastic leukemias; and treating malignant and nonmalignant diseases with cell subsets.

127 HSCs in the treatment of both malignant and nonmalignant diseases, as well as their use in gene ther

128 ngiogenic therapy outcomes for malignant and nonmalignant diseases.

129 vival after repeat liver transplantation for nonmalignant diseases.

130 the evaluation of HLA mismatches in HSCT for nonmalignant diseases.

131 tive treatment for a number of malignant and nonmalignant diseases.

132 potential curative therapy for malignant and nonmalignant diseases.

133 of new biologic treatments for malignant and nonmalignant disorders has enlarged the population at ri

134 ell transplantation (HSCT) for malignant and nonmalignant disorders is increasing, and late effects a

135 Twenty-three children with nonmalignant disorders received HLA-haploidentical hemat

136 ts in the pathogenesis of both malignant and nonmalignant disorders, yet the factors affecting their

137 allogeneic transplantation for children with nonmalignant disorders.

138 nd can now be applied to treat patients with nonmalignant disorders.

139 se effects of adult HSCs for these and other nonmalignant disorders.

140 disparities and may be a useful strategy for nonmalignant disorders.

141 n is an effective approach for patients with nonmalignant disorders.

142 ells in 27 children with either malignant or nonmalignant disorders.

143 ian 1-year survival compared with those with nonmalignant effusions (16.2% vs. 49.0%, respectively; l

144 ently in malignant T24 bladder cells than in nonmalignant embryonic kidney 293 or fibroblast NIH 3T3

145 (TEM) are antigens enriched in tumor versus nonmalignant endothelia.

146 rformed a microarray on tumor-associated and nonmalignant endothelium collected from patients with re

147 Studies in nonmalignant epithelial cells show that MUC1-C interacts

148 In nonmalignant epithelial cells, MUC1 interacts with caspa

149 ed preferentially in cancer cells but not in nonmalignant epithelial cells.

150 plasmablasts were expanded, as compared with nonmalignant epithelium.

151 d EC activation to levels found in quiescent nonmalignant epithelium.

152 ed RNA sequencing of EC cell lines and their nonmalignant ES cell line counterparts.

153 a primary lymphoid disorder characterized by nonmalignant expansion of a T-cell population able to pr

154 control--that of a woman with suspicious but nonmalignant findings at MR imaging--was similarly match

155 ese cell types are capable of distinguishing nonmalignant from malignant cells and the main reason fo

156 calization of these FL-like cells (FLLCs) in nonmalignant GC-rich tissues and the functional conseque

157 Such tumors share many common features with nonmalignant glial cells but, because of their insidious

158 on is a lifesaving therapy for malignant and nonmalignant hematologic diseases and metabolic disorder

159 ractive therapeutic option for patients with nonmalignant hematologic disorders and can mediate immun

160 intensity conditioning is a cure for several nonmalignant hematologic disorders that require chronic

161 HSCT has been a curative therapy for several nonmalignant hematologic disorders through the provision

162 conditioning regimen used in the context of nonmalignant hematological disorders leads to substantia

163 Most nonmalignant hematological disorders require transfusion

164 For many nonmalignant hematological disorders, HLA-matched bone m

165 transplantation (BMT) represents a cure for nonmalignant hematological disorders.

166 centives for new physicians to specialize in nonmalignant hematology.

167 logist positions that predominantly focus on nonmalignant hematology.

168 rigenic cells can co-opt normal functions of nonmalignant hematopoietic cells, promoting tumor progre

169 antly expressed in HepG2 cells compared with nonmalignant hepatocytes.

170 Nonmalignant HMEC (MCF10A, HMT3522 S1, and 184v) were ir

171 ed that CD13 (aminopeptidase N) expressed by nonmalignant host cells of unspecified types regulate tu

172 Unfortunately, donor T cells can attack nonmalignant host tissues and cause graft-vs-host diseas

173 iciency in allografted malignant (tumor) and nonmalignant (host) cells on tumor growth and metastasis

174 ion of glucose transporter type 3 (GLUT3) in nonmalignant human breast cells activated known oncogeni

175 In nonmalignant human cells, EGF stimulates robust activati

176 1, CCLP, HuCCT-1, and HuH-28, as well as the nonmalignant human intrahepatic biliary line, H69.

177 We used two nonmalignant human mammary epithelial cell lines that fo

178 Initially, nonmalignant human mammary epithelial cells (MCF-10A) we

179 Inactivation of RORalpha in nonmalignant human mammary epithelial cells inhibited SE

180 ry infection, one of whom developed a lethal nonmalignant illness.

181 ntribute to clinical responses by modulating nonmalignant immune cells.

182 s (122), hematologic malignancies (106), and nonmalignant immunosuppression (77).

183 Nonmalignant immunosuppression and hematologic malignanc

184 d into hematologic or solid malignancies and nonmalignant immunosuppression.

185 rs examined the potential for confounding by nonmalignant indications for surgery on breast cancer ri

186 trongly confounded by failure to account for nonmalignant indications for surgery.

187 tation is under investigation for a range of nonmalignant indications, including tolerance induction

188 r VLA-4-positive mouse 5TGM1-GFP myeloma and nonmalignant inflammatory host cells such as T cells and

189 e served as an additional control to provide nonmalignant inflammatory lymphadenopathy.

190 ates), structures previously associated with nonmalignant intestinal pathology, nearly universally (8

191 All complexes were inactive against nonmalignant keratinocytes but displayed variable activi

192 r objective was to describe the incidence of nonmalignant late complications and their association wi

193 The cumulative incidence of any nonmalignant late effect at 5 years after HCT was 44.8%

194 The burden of nonmalignant late effects after HCT is high, even with m

195 h nodes exhibited the lowest mean ADC of all nonmalignant lesions ([1.28 +/- 0.23] x 10(-3) mm(2)/sec

196 92%, 99%) and correctly identified 50 of 84 nonmalignant lesions as negative for cancer with a speci

197 d the negative predictive value for 50 of 53 nonmalignant lesions was 94.3% (95% CI: 88%, 99%).

198 Of 84 nonmalignant lesions, 82 were benign and two showed atyp

199 fluorescence imaging for lymph node mapping, nonmalignant lesions, nonsurgical purposes, or image gui

200 ponded, of whom 157 (64.1%) underwent PD for nonmalignant lesions.

201 sorting MCF-7 human breast cancer cells from nonmalignant leukocytes, while preserving the integrity

202 with HCC versus one of 31 (3%) patients with nonmalignant liver disease at risk for developing HCC (P

203 ology minimizing its toxicity to surrounding nonmalignant liver.

204 th NSCLC tumors and 91 patient controls with nonmalignant lung conditions, including histologically d

205 bservation of reduced risks of malignant and nonmalignant lung diseases in the region.

206 h TANs and neutrophils isolated from distant nonmalignant lung tissue were able to stimulate T cell p

207 her rate than epithelial cells isolated from nonmalignant lung tissue.

208 e syndrome (ALPS) presents in childhood with nonmalignant lymphadenopathy and splenomegaly associated

209 hat often manifest in childhood with chronic nonmalignant lymphadenopathy, hepatosplenomegaly, and re

210 We recently described a syndrome of chronic nonmalignant lymphadenopathy, splenomegaly, and autoimmu

211 Ls also express elevated Gal-1 compared with nonmalignant lymphocytes, demonstrating the ability of t

212 syndrome (ALPS) is characterized by chronic nonmalignant lymphoproliferation, accumulation of double

213 ptor-positive breast cancer cell lines and a nonmalignant mammary epithelial cell line.

214 Basal-like nonmalignant mammary epithelial cells also display an al

215 nhanced expression of antioxidant enzymes in nonmalignant mammary epithelial cells detached from ECM

216 TNBC cells, but not nonmalignant mammary epithelial cells, were dependent on

217 effect on cells null for MUC1 expression or nonmalignant mammary epithelial cells.

218 it had little effect on the survival of the nonmalignant MCF-10A breast epithelial cells.

219 Nonmalignant MCF-10A cells, however, were unaffected.

220 d 196 SMNs, 419 nonmelanoma skin cancers, 21 nonmalignant meningiomas, and 43 other benign neoplasms.

221 mouse model of Camurati-Engelmann disease, a nonmalignant metabolic bone disorder associated with inc

222 ession are due to genetic differences in the nonmalignant microenvironment.

223 We applied LQ-DGE to profile malignant and nonmalignant mouse and human cells, demonstrating its qu

224 lorectal tumor tissue compared with adjacent nonmalignant mucosa due in part to gene amplification de

225 expression and minimal inflammation seen in nonmalignant mucosa.

226 ments NK cell responses toward malignant and nonmalignant myeloid cells.

227 ment esophageal adenocarcinoma (N = 115) and nonmalignant (N = 183) biopsy tissues.

228 Desmoid tumors are nonmalignant neoplasms of mesenchymal origin that mainly

229 r and is characterized by both malignant and nonmalignant neurofibromas, which are composed of Schwan

230 ogenous leukemia, we show that malignant and nonmalignant neutrophils are more prone to NET formation

231 important step in melanoma progression from nonmalignant nevi with BRAF mutations.

232 Using the nonmalignant NF-kappaB-activated androgen-depleted mouse

233 rected mitochondrial accumulation of FerT in nonmalignant NIH3T3 cells increased their ETC complex I

234 ntly greater than admissions with underlying nonmalignant non-primary immunodeficiency hematologic di

235 mmon cause of Budd-Chiari syndrome (BCS) and nonmalignant, noncirrhotic portal vein thrombosis (PVT).

236 Data from the chronic nonmalignant pain literature suggest that toxicities may

237 they are efficacious in treatment of chronic nonmalignant pain remains controversial.

238 ances, their use in the treatment of chronic nonmalignant pain remains controversial.

239 ndations for the use of IDD for cancer pain, nonmalignant pain, and spasticity, as well as a new stud

240 As with chronic nonmalignant pain, multimodal interventions that incorpo

241 ment of cancer pain, spasticity, and chronic nonmalignant pain.

242 ications, including alcoholism, anxiety, and nonmalignant pain.

243 2010) was performed to find patients with a nonmalignant papillary breast lesion diagnosed at CNB.

244 Extrahepatic nonmalignant partial PVT improved spontaneously in 45% o

245 s with cirrhosis and untreated extrahepatic, nonmalignant partial PVT were followed up until the fina

246 sprouting and reorganization, which in other nonmalignant pathologies has been shown to generate and

247 crease cytotoxicity of dexamethasone against nonmalignant peripheral blood lymphocytes, mesenchymal s

248 umors, and fusion with host cells restores a nonmalignant phenotype, thereby providing a mechanism fo

249 ell lines, and decreased upon reversion to a nonmalignant phenotype.

250 ntains extracellular matrix and a variety of nonmalignant populations, including myeloid cells, lymph

251 ies of biliary brush samples (15 CCAs and 20 nonmalignant primary sclerosing cholangitis controls), a

252 compared with those having an operation for nonmalignant processes (2.1% [128 of 6213] vs 2.3% [232

253 In this study, we silenced DLC1 in nonmalignant prostate epithelial cells to explore its tu

254 omparison with RWPE1 cells (immortalized but nonmalignant prostate epithelial cells), suggesting an a

255 the TMPRSS2:ERG fusion in both malignant and nonmalignant prostate epithelial cells.

256 and prognostic potential was evaluated in 35 nonmalignant prostate tissue samples, 293 radical prosta

257 COS(hi) T cells and IFN-gamma mRNA levels in nonmalignant prostate tissues and incidental prostate tu

258 c prostate cancer specimens as compared with nonmalignant prostate tissues.

259 es of lung adenocarcinoma, mesothelioma, and nonmalignant pulmonary tissues (n = 285) as differentiat

260 with PVT, 60 were extracted who had chronic, nonmalignant PVT, after exclusion of those with sclerosi

261 ous xenoestrogen, bisphenol A (BPA), we used nonmalignant random periareolar fine-needle aspirates in

262 We have previously demonstrated in nonmalignant rat intestinal IEC-6 cells that schlafen 3

263 ponse trends occurred for both malignant and nonmalignant renal disease (12 and 13 deaths, respective

264 e exposure-response trends for malignant and nonmalignant renal disease.

265 g cancers (SMR = 0.7, 95% CI: 0.5, 0.9), and nonmalignant respiratory disease (SMR = 0.8, 95% CI: 0.6

266 norganic arsenic and ischemic heart disease, nonmalignant respiratory disease, and lung, skin, bladde

267 However, the effects on nonmalignant respiratory mortality are less studied, and

268 p of long-term exposure to air pollution and nonmalignant respiratory mortality in 16 cohorts with in

269 sociation between air pollution exposure and nonmalignant respiratory mortality.

270 ociations between air pollution exposure and nonmalignant respiratory mortality.

271 h factor (NGF) attenuates both malignant and nonmalignant skeletal pain.

272 melanoma and tumor suppressor activities in nonmalignant skin cancer.

273 cancer cells (sensitive to AS1411) and Hs27 nonmalignant skin fibroblasts (resistant to AS1411).

274 d developmental and neurological disease and nonmalignant skin photosensitivity.

275 at we can discriminate between malignant and nonmalignant stroma spectra with high sensitivity (93.56

276 hat targeting not only cancer cells but also nonmalignant stromal cells by T cells is required for th

277 rts on immunological strategies that destroy nonmalignant stromal cells essential for the survival an

278 ived specifically from either tumor cells or nonmalignant stromal cells that predict patient outcome

279 n in APN expression by both cancer cells and nonmalignant stromal cells within the tumor microenviron

280 at are surrounded by a diverse complement of nonmalignant stromal cells.

281 ions requiring additional work-up from other nonmalignant subtypes may further improve patient care.

282 ated KRAS gene can also be associated with a nonmalignant syndrome of autoimmunity and breakdown of l

283 umab infusions directed predominantly toward nonmalignant T cells rosetting around Reed-Sternberg cel

284 on in malignant T cells when cocultured with nonmalignant T cells, indicating an indirect mode of act

285 expression in cocultures with SEA-responsive nonmalignant T cells.

286 ed and primary patient-derived malignant and nonmalignant T cells.

287 evels in tumors relative to matched adjacent nonmalignant tissue from the same patient among 736 miRN

288 ences between MR parameters in malignant and nonmalignant tissue.

289 ignificantly different between malignant and nonmalignant tissue.

290 as significantly lower than that in adjacent nonmalignant tissue.

291 lignant tissues was significantly lower than nonmalignant tissues (P<0.002) and was negatively correl

292 s highly variable background expression from nonmalignant tissues and tumor heterogeneity.

293 However, malignant and nonmalignant tissues are usually distinguished on fluore

294 Because the uptake of CRL-3-(99m)Tc by nonmalignant tissues was negligible and retention in the

295 fferentiating malignant tissues from certain nonmalignant tissues with high glucose uptake.

296 ived from the tumor microenvironment or from nonmalignant tissues, have the capacity to reciprocally

297 -CTLA-4 antibody can occur in both tumor and nonmalignant tissues.

298 was upregulated significantly compared with nonmalignant tissues.

299 PD-L1 is also expressed by nonmalignant tumor-associated macrophages (TAMs), but th

300 -guanosine triphosphate activity, similar to nonmalignant, young HSC/Ps.